Christoph Lengauer

Background

Christoph Lengauer is Co-Founder and Chief Scientific Officer (CSO) of Curie.Bio, a Boston-based biotech venture firm and accelerator that launched in February 2023 with over $520 million in initial capital ¹². He holds a Ph.D. from the University of Heidelberg in Germany and an MBA with a focus on medical services management from the Johns Hopkins Carey Business School ³⁴. He studied human genetics at the University of Salzburg, Austria, and was the first in his family to attend college ⁵⁶.

Lengauer began his research career as a postdoc at IMP in Vienna in November 1992 before moving to Bert Vogelstein’s lab at Johns Hopkins University in July 1994, a move he has called “the most impactful decision of my professional career” ⁶. He spent 12 years at the Vogelstein lab (leading it for 9 of those years), where he discovered that all cancers are genetically unstable and was involved in the identification of several cancer driver genes, including BRAF and PIK3CA ³⁵⁶. He has authored more than 100 peer-reviewed scientific articles published in journals including Cell, Nature, and Science ³. He served as an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine ³.

Lengauer transitioned to the pharmaceutical industry, serving as Executive Director and Senior Unit Head of Oncology Discovery at the Novartis Institutes for Biomedical Research, where he contributed to the development of the SMO and CDK4 inhibitors ³⁶. He then served as Vice President and Global Head of Oncology Drug Discovery and Preclinical Development at Sanofi, leading a team of approximately 200 scientists ³⁶. Across his pharma career, he contributed to more than 25 drugs that reached human clinical trials and four FDA-approved medicines: Kisqali (ribociclib, breast cancer), Odomzo (sonidegib, basal cell carcinoma), Zaltrap (ziv-aflibercept, colorectal cancer), and Jevtana (cabazitaxel, prostate cancer) ³⁷. The Cancer Research Horizons board, where he serves as a Non-Executive Director, credits him with contributing to the development of ten drugs total ⁸.

Following his pharma career, Lengauer joined Blueprint Medicines as its founding Chief Scientific Officer and “Chief Drug Hunter,” where he led the clinical progression of BLU-285 (avapritinib) through breakthrough therapy designation by the FDA ³⁹. He joined Third Rock Ventures as a Venture Partner in 2016 and was promoted to Partner in December 2018 ³¹⁰. At Third Rock, he was a founding advising team member for Relay Therapeutics and served as interim CEO of Celsius Therapeutics ³¹⁰. He co-founded multiple biotech companies including Thrive Earlier Detection (where he served as Co-Founder and Chief Innovation Officer), Celsius Therapeutics, and MOMA Therapeutics ⁸¹¹¹².

In fall 2015, Lengauer was appointed CEO of the German Accelerator Life Sciences (GALS) by the German Federal Ministry for Economy, leading its buildout in Cambridge, MA and Berlin, Germany ¹³. He was recognized as one of BostInno’s “50 on Fire” in 2019, notably as one of the few individual honorees among mostly company winners ¹⁴. He is also a recipient of the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award, and the Novartis Oncology President’s Award for Top Innovator, and is an elected member of the Johns Hopkins Society of Scholars ³.

Lengauer is also known for his role in the Henrietta Lacks story, as featured in Rebecca Skloot’s bestselling book “The Immortal Life of Henrietta Lacks.” While at Johns Hopkins, he developed a fluorescent chromosome-painting technique using HeLa cells and invited the Lacks family to his lab in May 2001, giving Deborah Lacks the first opportunity to hold a vial of her mother’s cells ¹⁵.

Stated Thesis

As CSO of Curie.Bio, Lengauer publicly describes himself as leading a team of “hardcore drug hunters” who provide hands-on support to therapeutics founders ¹⁶. He has stated: “The team I lead at Curie are all hardcore drug hunters. Those are medicinal chemists and biochemists and project team leads and heads of R&D in pharma and biotech. There’s a lot of discovered, developed, and approved drugs in that group. And that team is expensive. That’s the Curie value proposition: that we have that team” ¹⁶.

Lengauer advocates for what he calls “responsible practice” in drug discovery — a middle path between the slow, inefficient approach of large pharma (the “fat way”) and the reckless, overly aggressive approach (the “slim way”). He emphasizes that successful drug hunting exists in the “margin,” defined by cultural elements like honesty, humility, transparency, and team support rather than technical prowess alone ⁵.

He has stated that Curie.Bio’s model enables broader innovation: “Our founders can do it because there’s a lot of value created at a low cost. If this encourages people to leave behind the job they have and encourages people to follow their crazy idea, that would be super for drug development and for patients” ¹⁷.

For founders, Lengauer recommends a budget of $7-15 million to reach a development candidate and an additional $30-50 million to reach meaningful clinical activity data, with a clear trajectory toward meaningful clinical outcomes ⁵. He advises academic founders to avoid secrecy, share ideas with trusted collaborators, and communicate clearly about the problem being solved, emphasizing that the biggest mistake founders make is attempting to succeed alone ⁵.

Inferred Thesis

Lengauer’s investment activity is conducted exclusively through Curie.Bio, where he serves as CSO alongside co-founders Zach Weinberg (CEO) and Alexis Borisy (Operating Chairman). Because Curie.Bio invests as a firm rather than through individual partner allocations, Lengauer’s personal portfolio is coextensive with Curie.Bio’s. Based on 8 verified investments (out of 26+ claimed by the firm as of January 2025 ¹⁸), the following patterns emerge. This sample represents approximately 30% of the known portfolio, so conclusions should be interpreted cautiously.

Stage distribution: 100% seed-stage investments (8 of 8). Every verified deal is a pre-Series A seed round, consistent with the firm’s stated focus ¹².

Sector breakdown: The portfolio is exclusively therapeutics. Based on verified investments: immunology/inflammation (2 of 8, 25% — Forward Therapeutics, Decrypt Biomedicine), neuroscience/psychiatry (2 of 8, 25% — Phrenix Therapeutics, Alkira Bio), degrader therapeutics (1 of 8, 12.5% — Differentiated Therapeutics), multiple sclerosis (1 of 8, 12.5% — Astoria Biologica). The remaining verified companies (Ambagon Therapeutics, R1 Therapeutics) have limited public information on therapeutic area ¹²¹⁹²⁰.

Modality mix: The portfolio spans small molecules (Forward Therapeutics), biologics/antibodies (Alkira Bio), and degraders (Differentiated Therapeutics), consistent with Curie.Bio’s stated “any modality” approach ¹².

Geographic distribution: Predominantly US-based, but with at least two investments in Australia-based companies (Alkira Bio, a Florey Institute spin-out in Melbourne, and Phrenix Therapeutics, a Monash University/Florey spin-out), suggesting genuine international reach ¹⁹²⁰.

Check size: $5-15 million in preferred stock per company, with an additional 7.5% of founder common stock in exchange for access to Curie.Bio’s shared drug discovery services. Forward Therapeutics received approximately $8 million in seed financing ²¹²².

Lengauer’s distinctive role: Unlike typical VC investors, Lengauer operates as a hands-on drug discovery leader, personally directing a team of over 100 drug hunters, medicinal chemists, and biotech operators who work as “fully integrated members” of portfolio company teams ²¹⁶. This operator-investor hybrid role is central to the Curie.Bio model and distinguishes his involvement from a traditional board-seat-only investor.

Co-investor patterns: At the fund level, Curie.Bio’s LPs include ARCH Venture Partners, GV, Leaps by Bayer, Casdin Capital, 5am Ventures, F-Prime Capital, and Evotec ¹². Brandon Capital co-invested in Phrenix Therapeutics at the portfolio level ²⁰.

Graduation rate: Forward Therapeutics, the first portfolio company, raised a $50 million Series A led by BVF Partners (with RA Capital and OrbiMed) in approximately 18 months from seed ²¹²².

Portfolio

Lengauer’s investments are made through Curie.Bio. The portfolio below reflects the firm’s verified investments.

This table represents approximately 30% of Curie.Bio’s claimed 26+ portfolio companies as of January 2025 ¹⁸. The majority of investments are not publicly disclosed. Prior to co-founding Curie.Bio, Lengauer was involved in founding or advising the creation of several companies at Third Rock Ventures, including Relay Therapeutics, Celsius Therapeutics, MOMA Therapeutics, Thrive Earlier Detection, and Blueprint Medicines ³⁸¹⁰.

In Their Own Words

“The team I lead at Curie are all hardcore drug hunters. Those are medicinal chemists and biochemists and project team leads and heads of R&D in pharma and biotech. There’s a lot of discovered, developed, and approved drugs in that group. And that team is expensive. That’s the Curie value proposition: that we have that team.” — Christoph Lengauer, C&EN interview, 2024 ¹⁶

“Our founders can do it because there’s a lot of value created at a low cost. If this encourages people to leave behind the job they have and encourages people to follow their crazy idea, that would be super for drug development and for patients.” — Christoph Lengauer, STAT News, November 2023 ¹⁷

“I became fascinated by Third Rock’s strategy to discover, launch and build great companies, based on bold ideas at the intersection of science, strategy, business and medicine.” — Christoph Lengauer, on joining Third Rock Ventures, BusinessWire, December 2018 ¹⁰

“This was the most impactful decision of my professional career.” — Christoph Lengauer, on his move to Bert Vogelstein’s lab at Johns Hopkins, IMP Alumni Portrait ⁶

What Founders Say

“You don’t have to reinvent the wheel. If you have an idea and a patient with challenges, pitch it.” — Toufike Kanouni, CEO & Co-Founder of Forward Therapeutics (Curie.Bio’s first portfolio company), C&EN interview, 2024 ¹⁶

“Developing therapeutic antibodies that target specific GPCRs has huge potential for creating safe, effective therapeutics.” — Daniel Scott, CEO of Alkira Bio, on the investment from Curie.Bio, Biotech Dispatch, July 2024 ¹⁹

“The investment from Curie.Bio will enable us to leverage our antibody discovery platform to tackle important diseases.” — Chris Draper-Joyce, CSO of Alkira Bio, Biotech Dispatch, July 2024 ¹⁹

No additional independently sourced founder testimonials describing their specific experience working with Lengauer or Curie.Bio were found. The quotes above are from portfolio company founders commenting on their investment announcements, not detailed accounts of the working relationship with Lengauer personally.

Connections

• Co-Founder, Curie.Bio — alongside Zach Weinberg (CEO) and Alexis Borisy (Operating Chairman) ¹²
• Former Partner, Third Rock Ventures (2016-2022) — alongside Abbie Celniker, Andrea van Elsas, Alan Ezekowitz (Venture Partners), and Jeffrey Tong (promoted to Partner alongside Lengauer in 2018) ³¹⁰²⁴
• Co-Founder and Chief Innovation Officer, Thrive Earlier Detection (2019) — alongside Bert Vogelstein, Kenneth Kinzler, and Nickolas Papadopoulos from Johns Hopkins ¹¹²⁵
• Founding CSO, Blueprint Medicines — worked with Alexis Borisy, who was also involved in Blueprint’s founding ³⁹
• Co-Founder and former interim CEO, Celsius Therapeutics ³¹⁰¹²
• Co-Founder, MOMA Therapeutics — serves as Director ⁸¹²
• Non-Executive Director, Cancer Research Horizons Board — inaugural Chair of the Therapeutic Innovation Board ⁸
• Scientific Advisory Board member, Mersana Therapeutics ²⁶
• Board member and Scientific Advisor, IDRx ²⁷
• Former Non-Executive Director, Hookipa Pharma (2018-2022) ²⁸
• Former Director, Presage Biosciences (since 2015) ²⁹
• Adjunct Associate Professor, Johns Hopkins University School of Medicine — maintained for 15+ years alongside colleagues Bert Vogelstein, Kenneth Kinzler, and Nickolas Papadopoulos ³⁴
• Podcast appearances: Nature Biotechnology “First Rounders” (November 2018) ³⁰, Nucleate Podcast “The Art and Science of Drug Hunting” (December 2025) ⁵, “Founders in Biotech” podcast ³¹

Sources